News
- 2025/03/03
- Nippon Kayaku announces completion of marketing authorization application of a novel ROS1 inhibitor, taletrectinib, for use in patients with advanced ROS1-positive Non-Small Cell Lung Cancer in Japan
- 2025/01/07
- Nippon Kayaku Selected as constituent of FTSE4Good Index Series, FTSE Blossom Japan Index, and FTSE Blossom Japan Sector Relative Index
- 2024/11/01
- Presentation of a global phase II clinical study of a novel ROS1 inhibitor, taletrectinib, in patients with advanced ROS1-positive Non-Small Cell Lung Cancer.
- 2024/10/10
- Annual update has been made to our Sustainability site.
- 2024/05/08
- Received ‘AA’ for the first time in MSCI ESG Ratings
- 2023/12/15
- NIPPON KAYAKU ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH BIOCHEETAH FOR VECanDx TM IN JAPAN
- 2023/10/19
- Updated information of sustainability
- 2023/10/18
- Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication
- 2023/09/25
-
Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody.
- 2022/11/16
-
Launch in Japan of Bevacizumab BS for I.V. Infusion 100mg・400mg “CTNK” ,an anti-VEGF humanized monoclonal antibody
- 2021/06/30
-
New Late-Breaking Data at The American Diabetes Association Show GlycoMark May Be an Effective Test for COVID-19 Severity
- 2020/07/06
-
Pict Leap Co., Ltd has developed “ Liquid Crystal Display Which Can Be Photographed By Infrared Camera ”
- 2020/02/07
-
Pict Leap Co., Ltd has developed "32-inch off-grid outdoor display system
